Biogen (NASDAQ:BIIB) issued an update on its FY 2021 earnings guidance on Thursday morning. The company provided earnings per share guidance of $17.500-$19.000 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $18.590. The company issued revenue guidance of $10.65 billion-$10.85 billion, compared to the consensus revenue estimate of $10.63 billion.Biogen also updated its FY21 guidance to $17.50-19.00 EPS.
NASDAQ BIIB traded down $0.80 during trading hours on Thursday, hitting $322.16. 9,697 shares of the company’s stock traded hands, compared to its average volume of 1,639,858. The stock has a fifty day simple moving average of $333.47. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.12 and a quick ratio of 1.75. The firm has a market capitalization of $48.50 billion, a price-to-earnings ratio of 17.07, a P/E/G ratio of 1.59 and a beta of 0.44. Biogen has a 52 week low of $223.25 and a 52 week high of $468.55.
Biogen (NASDAQ:BIIB) last announced its earnings results on Thursday, July 22nd. The biotechnology company reported $5.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.55 by $1.13. The company had revenue of $2.78 billion during the quarter, compared to analyst estimates of $2.61 billion. Biogen had a net margin of 23.89% and a return on equity of 42.04%. The firm’s quarterly revenue was down 24.6% compared to the same quarter last year. During the same period in the previous year, the business posted $10.26 earnings per share. As a group, equities analysts predict that Biogen will post 18.61 earnings per share for the current fiscal year.
In related news, insider Alfred Sandrock sold 7,672 shares of the company’s stock in a transaction dated Monday, June 7th. The shares were sold at an average price of $440.00, for a total value of $3,375,680.00. Following the completion of the sale, the insider now directly owns 2,919 shares of the company’s stock, valued at $1,284,360. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Brian S. Posner sold 360 shares of the company’s stock in a transaction dated Friday, June 4th. The stock was sold at an average price of $274.17, for a total transaction of $98,701.20. Following the completion of the sale, the director now directly owns 7,400 shares of the company’s stock, valued at $2,028,858. The disclosure for this sale can be found here. Corporate insiders own 0.54% of the company’s stock.
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.
Featured Article: Should I follow buy, hold and sell recommendations?
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.